Drug Index


Mechanism :

Lopinavir, an inhibitor of the HIV protease, prevents cleavage of the Gag-Pol polyprotein, resulting in the production of immature, non-infectious viral particles.

Indication :

  • Combination with other antiretroviral agents for the treatment of HIV-infection along with ritonavir

Contraindications :

Contraindicated in patients with known hypersensitivity to any of its ingredients, including ritonavir.

Dosing :

2 weeks to 6 months:
300 mg/75 mg (LPV/r)/m², or 16 mg/4 mg (LPV/r)/kg orally, every 12 hours.
6 months-18 years:
450 mg/m²/day along with ritonavir 108 mg/m²/day PO divided in 12 hours.

Adverse Effect :

Increased spontaneous bleeding in patients with haemophilia, liver function abnormalities, pancreatitis; dyspepsia, arthralgia, new onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus, hyperglycemia, anaphylactoid reactions, urticaria, vasculitis, depression, oral paraesthesia, rash including erythema multiforme and Stevens-Johnson syndrome, hyperpigmentation, alopecia, paronychia, ingrown toenails, pruritus, redistribution/accumulation of body fat, urolithiasis, nephrolithiasis, increased serum cholesterol, increased serum triglycerides, myocardial infarction.

Interaction :

CYP3A Drugs: Lopinavir is an inhibitor of CYP3A (cytochrome P450 3A) both in vitro and in vivo. Co-administration of drugs primarily metabolized by CYP3A (e.g., dihydropyridine calcium channel blockers, HMG-CoA reductase inhibitors, immunosuppressants and sildenafil) may result in increased plasma concentrations of the other drugs that could increase or prolong their therapeutic and adverse effects.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function. Monitor closely

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnlikely to be dialysed. Dose as in GFR<10 mL/min
HDUnlikely to be dialysed. Dose as in GFR<10 mL/min
HDF/High fluxUnlikely to be dialysed. Dose as in GFR<10 mL/min
CAV/VVHDUnknown dialysability. Dose as in normal renal function

Hepatic Dose :

Use with caution in hepatic impairment. Mild to moderate impairment: There are no dosage adjustments recommended; however, lopinavir AUC may be increased ~30% in patients with mild to moderate hepatic impairment; use with caution.
Severe impairment: No data is available. It should not be given in patients with severe impairment.
03/20/2024 21:55:26 Lopinavir
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0